Cefma children's suspension powder for oral suspension 40mg/5ml 100ml

Cefma Children's Suspension is indicated for the treatment of infections caused by pathogens sensitive to the drug:

Composition

active ingredient: cefpodoxime;

5 ml of oral suspension contains 52.219 mg of cefpodoxime proxetil, equivalent to 40 mg of cefpodoxime;

excipients: silicon dioxide, iron oxide (E 172), talc, sorbitan trioleate, lemon flavor, citric acid anhydrous, sodium chloride, sodium benzoate (E 211), orange flavor, aspartame (E 951), guar gum (E 412), sucrose.

Contraindication

Hypersensitivity to cefpodoxime, cephalosporin drugs or any of the components of the drug.

History of immediate or severe hypersensitivity reaction to penicillin or any other type of beta-lactam drug.

Since the medicine contains aspartame, it is not used in children suffering from phenylketonuria.

For newborns up to 28 days of age and infants aged 4 weeks to 3 months with renal insufficiency, treatment with the drug is not recommended, as there is no such experience.

Method of application

The recommended dose for children is 8 mg/kg/day, administered in two divided doses 12 hours apart. A graduated syringe (10 ml) with 0.5 ml graduations is supplied with the bottle to ensure accurate dosing.

The suspension is prepared by adding water to the vial up to the calibration mark and shaking thoroughly until a thoroughly dispersed suspension is obtained.

Application features

Pregnant women

The drug is intended for use in children.

Children

The drug should be used in children aged 4 weeks to 12 years. Treatment with the drug is not recommended for infants aged 4 weeks to 3 months with renal insufficiency, as there is no such experience.

Drivers

The drug is intended for use in children.

Overdose

Symptoms: nausea, vomiting, abdominal pain, diarrhea. In patients with renal insufficiency, overdose may lead to the development of encephalopathy, which is usually reversible after a decrease in cefpodoxime plasma levels.

Treatment.

In case of overdose with cefpodoxime, supportive and symptomatic therapy should be administered. Hemodialysis, peritoneal dialysis.

Adverse reactions

On the part of the digestive tract: often - anorexia, intragastric pressure, gastrointestinal discomfort, nausea, vomiting, abdominal pain, flatulence, diarrhea. Bloody diarrhea may be a symptom of enterocolitis; rarely - thirst, tenesmus, dyspepsia, dry mouth, decreased appetite, constipation, candidal stomatitis, eructation, gastritis, mouth ulcers, acute pancreatitis, pseudomembranous colitis.

Interaction

Bioavailability increases when the drug is taken with food.

Cefpodoxime should not be used concomitantly with bacteriostatic antibiotics (e.g. chloramphenicol, erythromycin, sulfonamides or tetracyclines) as the effect of cefpodoxime may be reduced.

A false-positive reaction for glucose in urine may be detected using Benedict/Fehling's solutions or copper sulfate, but such a reaction has not been detected using tests based on enzymatic glucose oxidase reactions.

Storage conditions

Store at a temperature not exceeding 25 °C.

The prepared suspension should be stored at 2 - 8 °C for no more than 14 days.

Keep container tightly closed.

Keep out of reach of children.

Shelf life: 3 years.